Cipla peers

·Pharma & HealthChart ›

Companies like Ciplalatest year

CiplaCIPLA · FY26 · this company
Market cap₹1,10,313
P/E28.43×
Sales growth−2.4%
ROE11.8%
Sun Pharmaceutical IndustriesSUNPHARMA · FY26
Open ›
Market cap₹4,21,677
P/E36.77×
Sales growth+10.5%
ROE14.7%
Dr. Reddy's LaboratoriesDRREDDY · FY26
Open ›
Market cap₹1,11,506
P/E26.49×
Sales growth−1.5%
ROE11.8%
LupinLUPIN · FY26
Open ›
Market cap₹90,192
P/E16.90×
Sales growth+32.0%
ROE26.9%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CIPLA₹1,365.60

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.10L Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
CIPLA
FY26
SUNPHARMA
FY26
DRREDDY
FY26
LUPIN
FY26
Peer
Average
Valuation — at last close
P/E28.43×36.77×26.49×◆ 16.90×26.72× +6%
P/B3.20×5.05×◆ 2.94×4.02×4.00× -20%
EV/EBITDA17.28×22.19×17.19×◆ 9.86×16.42× +5%
Market Cap₹1.10L Cr₹4.22L Cr₹1.12L Cr₹90,192 Cr₹2.08L Cr -47%
Growth
Revenue CAGR 3Y7.37%10.03%10.96%◆ 18.88%13.29% -45%
Revenue CAGR 5Y8.01%11.78%12.09%◆ 13.02%12.30% -35%
Net Income CAGR 3Y10.88%10.57%-2.66%◆ 128.70%45.54% -76%
Revenue YoY (latest Q)-2.44%10.46%-1.48%◆ 32.04%13.67% -118%
Net Income YoY (latest Q)-37.08%◆ 26.53%-31.69%16.01%3.62% -1125%
Profitability
EBITDA Margin20.89%30.33%19.15%◆ 31.53%27.00% -23%
Net Income Margin13.71%◆ 19.69%12.34%19.16%17.06% -20%
Return on Common Equity11.82%14.74%11.75%◆ 26.90%17.80% -34%
Return on Capital Employed13.87%18.48%11.30%◆ 32.38%20.72% -33%
Return on Assets9.67%11.46%7.73%◆ 15.85%11.68% -17%
Credit & Quality
Total Debt/Equity◆ 0.01×0.05×0.16×0.26×0.16× -94%
Interest Coverage◆ 85.90×43.65×11.76×17.12×24.18× +255%
Scale — latest FY
Revenue / Total Income₹28,163 Cr₹58,462 Cr₹33,700 Cr₹27,958 Cr₹40,040 Cr -30%
Net Income₹3,862 Cr₹11,509 Cr₹4,158 Cr₹5,355 Cr₹7,007 Cr -45%
Total Assets₹42,496 Cr₹1.09L Cr₹58,123 Cr₹38,365 Cr₹68,424 Cr -38%
EPS₹48.03₹47.8₹50.41₹116.75₹71.65 -33%
Book Value per Share₹426.24₹348.31₹453.79₹490.99₹431.03 -1%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.